Latest European Association of Urology Stories

Global Launch Generates Strong Support for SonaCare Medical's Urology Platform Technology to Provide HIFU Surgical Ablation Systems for a Wide Range of Urological Indications CHARLOTTE, N.C., April 2, 2013 /PRNewswire/ -- SonaCare Medical, a leader in minimally invasive high intensity focused ultrasound (HIFU) technology, successfully launched two new products at the recent European Association of Urology (EAU) Congress in Milan, Italy. Generating significant interest in its...

The initial study results of the Zometa European Study (ZEUS) showed no difference in the incidence of bone metastases between the Zometa group and control arm, said Prof. Manfred Wirth during the closing and fourth plenary session of the 28th Annual EAU Congress which ends today. "There is no difference in the incidence of bone metastases and there is no difference in survival," said Wirth in his brief presentation on whether Zometa can prevent bone metastases in high risk, metastatic...

Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumors might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to a new study to be presented at the 28th Annual EAU Congress currently on-going in Milan. "The inactivation of the von Hippel-Lindau gene (VHL) is a common event in ccRCC and finally leads to the induction of HIF1α target genes such as CA9 and VEGF," write the authors....

Small kidney tumors have an aggressive potential and should be treated, according to a the results of a large multi-center study presented at the 28th Annual EAU Congress in Milan. "Many clinicians regard small renal cell cancer as having a benign biologic behavior and non-operative surveillance protocols are often being used in patients with small renal tumors," write the authors in the findings. "The aim of this large retrospective multi-center study was to evaluate the prevalence of...

At the 28th Annual EAU Congress currently ongoing in Milan until Tuesday, W. Tan and colleagues presented their study on neoadjuvant cisplatin-based chemotherapy which showed that epigenetic changes are potential key drivers in the development of chemo resistance in bladder cancer. Neoadjuvant cisplatin-based chemotherapy is recommended for patients with muscle invasive bladder cancer. Cisplatin-based regimes have similar efficacy with complete response in 30% a survival advantage if 16%...

Men who participate in biennial PSA based screening have a lower risk of being diagnosed as well as dying from prostate cancer up to 9 years after their last PSA test, according to the results of a new study to be presented at the 28th Annual EAU Congress in Milan A joint Swedish-UK study aimed to examined the risk of developing prostate cancer after last invitation to screening. This investigation follows up on previous publication from the Göteborg randomized screening trial (part of...

A genetic score based on PCa risk-associated single nucleotide polymorphisms (SNPs) is an independent predictor of prostate biopsy outcomes, suggest the results of a new study conducted by a group from the Department of Urology Huashan Hospital, Fudan University in Shanghai, China. The authors, who relate their findings to the male population in China, also suggest that this score can improve predictive performance of existing clinical variables, especially for patients with a total PSA...

New Products Build on Growing Adoption of SonaCare Medical HIFU Technologies Following a Record 230% Increase in International Sales and a 3X Expansion in International Distributors CHARLOTTE, N.C., March 14, 2013 /PRNewswire/ -- SonaCare Medical, LLC (SonaCare Medical), a leader in minimally invasive high intensity focused ultrasound (HIFU) technologies, will showcase two new HIFU products at the 28(th) annual European Association of Urology (EAU) Congress, in Milan, Italy, March...

The safety of the patient is the prime consideration During the final day of the 28th Annual EAU Congress, which will take place on 15-19 March 2013 in Milan, the European Association of Urology will release its official policy statement on live surgery ethics. The statement and accompanying commentary will be delivered by Mr. Keith Parsons (Liverpool, UK), who chairs the EAU Guidelines Office and is a member of the working panel which was tasked with formulating the policy. Chaired by...

AMSTERDAM, The Netherlands, January 28, 2013 /PRNewswire/ -- Elsevier [http://www.elsevier.com ], a world-leading provider of scientific, technical and medical information products and services, welcomes Dr. James Catto, MB ChB, PhD, FRCS (Urol), of the Academic Urology Unit, Royal Hallamshire Hospital in Sheffield (UK) as the new Editor-in-Chief of European Urology, the official journal of the European Association of Urology (EAU). The journal has been a prestigious...